Mauna Kea Technologies SA unveiled its new subsidiary CellTolerance1, fully dedicated to its unique program for the detection and treatment of food intolerances associated with Irritable Bowel Syndrome (IBS). CellTolerance? is a unique program designed with physicians and dietitians to detect and treat food intolerances through personalized dietary monitoring, live cell-response visualization via intestinal barrier microscopic response to selected foods and supervised elimination diets.

It is rooted in more than a decade of research and peer-reviewed publications, including new data presented at the Digestive Disease Week® (DDW) 2024 Conference held in Washington, DC. To best develop the CellTolerance? program, a new wholly owned subsidiary will soon be incorporated (?CellTolerance?), with the prospect of eventually operating as an independent, lean company with specific agreements, ensuring the availability of the Cellvizio technology platform as a key component of the CellTolerance?

program. CellTolerance will also aim at providing patients, providers and partners with innovative digital tools to monitor patients and collect a vast quantity of real world and clinical data. This unique multi-scale dataset (endoscopy, endomicroscopy, clinical data, etc.) will be leveraged to develop advanced AI models offering unprecedented clinical insights.

These insights could empower pharmaceutical and nutrition companies to tailor personalized treatments, optimize nutritional plans, and predict individual responses to therapies and dietary interventions. By integrating comprehensive data analytics and AI, CellTolerance aims to transform healthcare delivery and nutrition management, ultimately enhancing patient outcomes and advancing medical research. It is also envisioned that CellTolerance will quickly open its capital to venture capital funds specializing in nutrition, wellness, microbiome, gut health and related activities to fund the development of its program independently.

The CellTolerance? program is intended to be launched at scale in key markets such as the United States, France, Germany, Italy and Switzerland. The addressable market in these countries is highly significant, representing an opportunity estimated at $1.5 billion.

To best capitalize on this opportunity and maximize the reach of its program, CellTolerance intends to form strategic partnerships with clinic networks which see the program as a unique opportunity to expand their service offerings. By working closely with networks of clinics, CellTolerance will ensure continuous training and ongoing support for healthcare professionals, enabling optimal use of its technologies. This strategy aims to establish CellTolerance?

as the reference solution for identifying and treating food intolerances while reducing marketing costs through partners' marketing infrastructures.